Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
SUPN
#1407
Supernus Pharmaceuticals, Inc.
54.730
0
+0.48%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+0.48%
Aylık değişim
+10.77%
6 aylık değişim
+1.35%
Yıllık değişim
+1.35%
Önceki kapanış
54.470
0
Open
54.730
0
Bid
Ask
Low
54.730
0
High
54.730
0
Hacim
97
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
SUPN
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
55.22 M
55.81 M
55.99 M
56.07 M
57.34 M
—
Valuation ratios
Enterprise value
1.69 B
1.95 B
1.72 B
1.62 B
2.59 B
7.88 B
Price to earnings ratio
28.61
27.39
29.5
27.41
-140.56
-56.25
Price to sales ratio
2.67
3.06
2.74
2.66
3.95
12.4
Price to cash flow ratio
10.07
11.77
11.15
9.47
37.21
69.6
Price to book ratio
0.46
1.95
0.45
0.43
0.64
3.48
Enterprise value to EBITDA ratio
5.5
3.57
6.84
6.56
17.69
34.66
Profitability ratios
Return on assets %
0.03
0.01
-0.01
-0
0
0
Return on equity %
0.04
0.01
-0.01
-0
0
0
Return on invested capital %
9.81
4.03
0.1
-1.89
9.66
11.91
Gross margin %
89.99
85.01
89.48
89.83
90.13
354.45
Operating margin %
19.66
12.29
-6.85
-5.06
18.71
19.1
EBITDA margin %
51.41
35
27.61
33.13
-5.62
90.12
Net margin %
21.91
8.8
-7.89
-0.7
0.06
0.27
Liquidity ratios
Quick ratio
1.98
2.16
2.26
2.43
1.47
8.32
Current ratio
2.2
2.35
2.44
2.58
1.8
9.16
Inventory turnover
0.27
0.44
0.3
0.36
0.25
1.36
Asset turnover
0.13
0.13
0.11
0.12
0.14
0.5
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.96
0.79
0.55
1.03
-1.1
1.28
EBIT per share
1.26
0.75
0.38
0.59
-0.63
1.08
EBITDA per share
1.62
1.09
0.74
0.97
-0.19
2.6
Total debt per share
—
—
—
—
—
—
Cash per share
0.57
1.24
2.07
2.55
2.7
8.56
Net current asset value per share
11.47
12.26
12.31
13.03
10.58
48.18
Tangible book value per share
6.27
7.09
7.37
8.21
5.47
28.14
Working capital per share
6.25
7.04
7.26
7.98
4.69
26.97
Book value per share
18.05
18.51
18.45
18.77
18.7
74.43
Haberler
TD Cowen erhöht Kursziel für Supernus Pharmaceuticals nach Onapgo-Relaunch
TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch
Aktie von Supernus Pharmaceuticals auf neuem 52-Wochen-Hoch bei 57,76 US-Dollar
Supernus Pharmaceuticals stock hits 52-week high at $57.76
Supernus: Cantor Fitzgerald bestätigt "Overweight"-Rating dank gesicherter Lieferkette
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
Supernus: EPS verfehlt Schätzungen um 0,48 $ - Umsatz besser als erwartet
Supernus earnings missed by $0.48, revenue topped estimates
Supernus vor Bewährungsprobe: Quartalszahlen nach Q3-Verlust im Fokus
Supernus faces earnings test after Q3 shock to profitability
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline